|1.||Pieters, Rob: 20 articles (11/2014 - 04/2003)|
|2.||Pui, Ching-Hon: 15 articles (07/2015 - 12/2002)|
|3.||Asselin, Barbara L: 12 articles (12/2015 - 03/2007)|
|4.||Relling, Mary V: 12 articles (07/2015 - 08/2004)|
|5.||Avramis, Vassilios I: 12 articles (07/2015 - 03/2002)|
|6.||Silverman, Lewis B: 11 articles (12/2015 - 03/2007)|
|7.||Sallan, Stephen E: 10 articles (12/2015 - 03/2007)|
|8.||Rizzari, Carmelo: 9 articles (08/2015 - 10/2005)|
|9.||Hunger, Stephen P: 9 articles (07/2015 - 02/2008)|
|10.||Relling, M V: 9 articles (06/2014 - 04/2000)|
|1.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/01/2008 - "The outcome of pediatric acute lymphoblastic leukemia (ALL) has improved dramatically over the last 40 years through a systematic approach of well-designed large trials including use of asparaginase. "
06/01/2012 - "The use of L-asparaginase (ASNase) to modify amino acid metabolism is one of the most effective chemotherapeutic means of inducing remission in acute lymphoblastic leukemia (ALL). "
02/01/2008 - "L-asparaginase (ASNase) is one of the most effective chemotherapeutic means for inducing remission in acute lymphoblastic leukemia. "
03/27/2014 - "This study prospectively analyzed the efficacy of very prolonged courses of pegylated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase in pediatric acute lymphoblastic leukemia (ALL) patients. "
05/01/1987 - "We studied platelet function and plasma coagulation parameters in 12 pediatric patients with acute lymphoblastic leukemia (ALL) receiving daily L-asparaginase as a single agent when in complete remission. "
03/01/1982 - "Similarly, the polymeric form of L-asparaginase is more effective in inhibiting cell growth of human pancreatic tumor cells grown in tissue culture. "
07/01/2014 - "Class II asparaginase from Escherichia coli (EcA), a homotetramer with a mass of 138 kDa, is especially effective in cancer therapy. "
01/01/2014 - "The present work could be seen as producing a modified L-asparaginase with improved activity and stability and can be a potential source for developing therapeutic agents for cancer treatment."
12/01/1969 - "Of 28 coliforms, five strains of Escherichia coli were particularly active in elaborating L-asparaginase 2, the form of the enzyme useful in the treatment of some forms of cancer. "
06/01/1983 - "After injection of 5.0 IU ip of L-asparaginase in microparticles, partial remission was induced, generally, however, the cancer relapsed and killed the mice within 2-3 weeks. "
06/01/1982 - "In addition, preimmunization with the native enzyme prevented the antitumor activity of the native enzyme but did not affect the therapeutic efficacy of the modified L-asparaginase against the lymphoma."
01/01/2013 - "coli-derived asparaginase as a therapeutic option for pets with lymphoma."
01/01/2013 - "Effects of cold-stored asparaginase on cell proliferation and cytotoxicity were measured in feline (MYA-1, F1B) and canine (17-71, OSW) lymphoma cells. "
01/01/2013 - "coli-derived asparaginase retains enzymatic and antineoplastic activity in canine and feline lymphoma cells after cold storage. "
01/01/2013 - "coli-Derived L-Asparaginase Retains Enzymatic and Cytotoxic Activity In Vitro for Canine and Feline Lymphoma after Cold Storage."
06/01/1968 - "l-Asparaginase is now known to be a potent antineoplastic agent in animals and has given complete remission in some human leukemias. "
01/01/1981 - "Asparaginase is markedly more effective against human leukemia T-cells in vitro than against several types of B-lymphocytes. "
01/01/1979 - "The results of this study demonstrate that the intramuscular method of administering L-asparaginase is as effective, but less toxic, than the intravenous method for children with advanced leukemia. "
01/01/1979 - "A study was done to evaluate intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. "
01/01/1971 - "[Results of the treatment of acute leukemias in children with asparaginase (critical study of 34 cases)]."
12/01/1999 - "The 4-year EFS rate for patients with a first complete remission >/= 18 months was 83.3% +/- 5.3%, and for those with a first complete remission less than 18 months, it was 46.2% +/- 10.2% (P =.0002.) There was a low incidence of neurologic toxicity and an unexpectedly high rate of allergic reactions to L-asparaginase. "
07/01/2010 - "L-asparaginase is effective in the treatment of malignant diseases, but it has been associated with hypersensitivity reactions in 5% to 45% of the patients. "
10/01/2012 - "Hypersensitivity reactions limit the use and efficacy of asparaginase products. "
01/01/1997 - "In addition, its use in patients with silent hypersensitivity may maintain the efficacy of asparaginase. "
07/01/2014 - "This study further established the safety profile of asparaginase Erwinia chrysanthemi in patients with ALL or LBL who had a hypersensitivity reaction to an E. "
|6.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Stem Cell Transplantation